Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c/C-peptide Ratio, Neutrophil/HDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.

NCT07132489 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT07132489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07132489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Validation of Novel Metabolic, Inflammatory, and Hepatic-Renal Biomarkers-HbA1c/C-peptide Ratio, Neutrophil/HDL Ratio, and ALBI Score-for Predicting the No-Reflow Phenomenon After Primary PCI in Patients With STEMI.
Lead sponsor
Assiut University
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 1, 2028
Enrollment
114 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myocardial infarction, no reflow phenomenon